D&H National Research Centers | Miami, FL

Research site

(Unclaimed)

Location

8485 Bird Road Suite 307, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

Cenerimod

Dexlansoprazole

EDP-235

MTX

SAB-185

Dulaglutide

Methotrexate

LY2189265

Upadacitinib

Ridinilazole

Parent organization

This site is a part of D&H National Research Centers

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 33 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling

NASH - Nonalcoholic Steatohepatitis

Drug: Placebo

Drug: IVA337

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus (OPUS-2)

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to sever...

Enrolling

Lupus Erythematosus, Systemic

Drug: Cenerimod

Drug: Placebo

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation...

Enrolling

Type 2 Diabetes

Drug: Dulaglutide

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Active, not recruiting

Atopic Dermatitis

Eczema Atopic Dermatitis

Drug: Placebo

Drug: Camoteskimab

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube...

Enrolling

Erosive Esophagitis

Drug: Dexlansoprazole

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube...

Enrolling

Gastroesophageal Reflux Disease (GERD)

Drug: Dexlansoprazole

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Active, not recruiting

Gout

Drug: Methotrexate

Biological: Pegloticase

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to...

Enrolling

Insomnia

Drug: Daridorexant 10 mg

Drug: Daridorexant 25 mg

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus (OPUS OLE)

The goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients with moderate to severe sympto...

Invitation-only

Lupus Erythematosus, Systemic

Drug: Cenerimod